Filament Health Corp.

FLHLF

CA31685W1068

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 09:52:09 2024-04-26 am EDT			5-day change	1st Jan Change
0.0344 ^USD	-1.29%		-8.75%	-36.41%

Apr. 03	Filament Health Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Filament Health Corp. Announces Appointment of Michael Messinger to Its Board of Directors and Chair of the Audit Committee	CI

Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital

July 23, 2023

On July 24, 2023, Filament Health Corp. closed the transaction. The company has issued 27,777,781 units for gross proceeds of CAD 2,500,000.

Latest news about Filament Health Corp.

Filament Health Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Filament Health Corp. Announces Appointment of Michael Messinger to Its Board of Directors and Chair of the Audit Committee	Mar. 28	CI
Filament Health Corp. Announces Chief Financial Officer Changes	Mar. 28	CI
Filament Health Corp. Announces Shipments of Botanical Psilocybin to Four Countries for Clinical Investigation	Mar. 19	CI
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel	Feb. 15	CI
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders	Jan. 31	CI
Filament Health Completes the First Export of Biological Psilocybin to Australia	Jan. 17	CI
Filament Health Announces Change to Board of Directors	Jan. 02	CI
Filament Health Corp. (OTCPK:FLHL.F) cancelled the acquisition of Jupiter Acquisition Corporation from a group of shareholders in a reverse merger transaction.	Dec. 17	CI
Filament Health Corp. announced that it has received CAD 0.9 million in funding from Negev Capital	Dec. 05	CI
Filament Health Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder	23-10-09	CI
Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital	23-09-28	CI
Filament Health Corp. Enters Licensing Agreement with Reset Pharmaceuticals Inc	23-08-30	CI
Filament Health Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-13	CI
Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010	23-08-08	CI
Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital	23-07-23	CI
Jupiter Acquisition Corporation entered into a definitive agreement to acquire Filament Health Corp. (OTCPK:FLHL.F) from shareholders for approximately $150 million.	23-07-18	CI
Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital	23-07-18	CI
Filament Health Corp. to Supply Psilocybin for Two Clinical Trials	23-07-07	CI
Filament Health Corp. Enters Exclusive Licensing Agreement with NeoLumina Bioscience Inc	23-06-30	CI
Filament Health Corp. Announces Interim Results from Phase I Clinical Trial at the University of California, San Francisco	23-05-30	CI
Filament Health Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Pharmala Biotech Holdings Inc. and Filament Health Corp. Announce GMP Release of EMP Capsules	23-04-11	CI
Filament Health Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Companyâs platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Companyâs first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The Company's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld), and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Companyâs internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
FILAMENT HEALTH CORP.	-36.41%	7.26M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology